Constipation can happen during GLP-1 therapy because appetite, fluid intake, fiber intake, movement, and digestion may all change
In January of this year, the FDA noted that it had "received adverse event reports after patients used compounded semaglutide" and that "patients should not use a compounded drug if an approved drug is available to treat a patient." In July, the agency followed up with a notice that it had "received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products." And in August, Eli Lilly, the maker of Zepbound and Mounjaro, sent a series of cease-and-desist letters to providers urging them to stop prescribing compounded versions of those drugs
If someone has type 2 diabetes and/or obesity, however, their naturally occurring GLP-1 may not be as robust
FOR SEMAGLUTIDE SOURCE: MedlinePlus